PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline
William P. Tew(Memorial Sloan Kettering Cancer Center), Elise C. Kohn(National Cancer Institute), Stéphanie Lheureux(Princess Margaret Cancer Centre), Christina Lacchetti(Washington Hospital), Kathleen Maxian(Ovarian Cancer Research Alliance), Christine Walsh(Cedars-Sinai Medical Center), Michael A. Bookman(National Cancer Institute), Joyce F. Liu(Duke University), Susana Banerjee(Royal Marsden NHS Foundation Trust), Kathleen N. Moore(University of Oklahoma Medical Center), Jung Min Lee(Kyung Hee University), Patricia Rodríguez(University of Minnesota), Carolyn Y. Muller(University of New Mexico), Monica B. Jones(Anne Arundel Medical Center), Annie Ellis(SHARE), Shannon N. Westin(The University of Texas MD Anderson Cancer Center)
Cited by 318
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
Predicting Chemotherapy Toxicity in Older Adults With Cancer: A Prospective Multicenter Study
|Journal of Clinical Oncology|2011|1.8k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k